Oct 29, 2024
Vaxinano Secures €6 Million ($6.5M) Investment to Bring Nasal Vaccines Closer to Clinical Testing. (Source)
Clover’s SCB-1019 RSV vaccine shows promising results in Phase 1 clinical trials, demonstrating superiority over GSK’s Arexvy. (Source)
Oct 28, 2024
Vaxxas Partners with NIH to Develop Needle-Free RSV Vaccine. (Source)
Oct 24, 2024
GSK reports positive Phase 3b trial data for Arexvy, its RSV vaccine, in younger adults. (Source)
Oct 22, 2024
Pfizer secures expanded FDA approval for RSV vaccine. (Source)
Oct 17, 2024
Bavarian Nordic’s mpox vaccine generates a similar immune response in both adolescent and adult populations (study by the NIH). (Source)
ExpreS2ion Biotechnologies has partnered with Serum Institute of India for malaria vaccine development. SIIPL will obtain rights to develop, manufacture, and commercialize the malaria vaccines currently in Phase I and Phase II together with the University of Oxford. (Source)
ClearB Therapeutics partners with Adjuvance Technologies to develop a novel saponin adjuvant, TQL-1055, for chronic hepatitis B. Pre-clinical data will be presented at AASLD 2024. Therapeutics vaccine, hepatitis B, vaccine adjuvant (Source)
Oct 16, 2024
Sanofi’s FLUBLOK® influenza vaccine label has been updated to include results from a major safety study conducted in pregnant individuals. (Source)
Merck’s 21-valent pneumococcal conjugate vaccine, CAPVAXIVE™, has been shown to elicit strong immune responses in adults who are at increased risk of contracting pneumococcal disease. (Source)
US FDA halts Novavax’s combo COVID-flu shot trial. (Source)
Oct 14, 2024
Transgene’s TG4001 cancer vaccine has failed in Phase II clinical trials, despite showing some positive signs of efficacy. Cancer vaccine, cervical cancer, canogenital cancer, oncolytic virus (Source)
Oct 10, 2024
Valneva aims to achieve sustained profitability for its Lyme disease vaccine, VLA15, by the year 2027. This is dependent on successful regulatory approval and subsequent commercialization by its partner, Pfizer. (Source)
